Northfield Blood Substitute Rejected by FDA
The Food and Drug Administration refused to approve the human blood substitute, Polyheme, for use in trauma patients suffering from severe blood loss.
Northfield, Polyheme Not Long for This World
An FDA decision to not convene a panel of blood experts to review Northfield Labs' Polyheme is a signal the agency already has decided to reject the blood substitute for approval.
Blood Sub or Not, Northfield's a Negative
With the odds stacked against Polyheme being approved, investors should think hard before chasing this stock.
Biotech Notebook: Progenics, Wyeth
Projecting potential market share for newly approved Relistor; monitoring exec moves at Introgen; and more.
Feuerstein's Biotech-Stock Mailbag
Vertex's cystic fibrosis compound shows promise, but be cautious in your enthusiasm. Also, an update on the quest for blood substitutes.
Disney Mobile Game Opens Up a New Universe
Familiar Disney characters populate an alternate reality in new interactive game.
Birth Control Stocks May Benefit From the Reversal of Roe v. Wade
The historic Supreme Court decision may force women to make different choices.
Roe Decision Forces Disney, Netflix to Take a Political Stand
Disney, JP Morgan Chase, and outgoing Meta COO Sheryl Sandberg are just a few speaking out against the ruling.